<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00076804</url>
  </required_header>
  <id_info>
    <org_study_id>1R01AI055359-01A1</org_study_id>
    <secondary_id>1R01AI055359-01A1</secondary_id>
    <nct_id>NCT00076804</nct_id>
  </id_info>
  <brief_title>Helping HIV Infected Patients in South Africa Adhere to Drug Regimens</brief_title>
  <official_title>DOT-HAART for HIV-Infected South African Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three or more anti-HIV drugs are taken in combination as part of a treatment regimen. These
      drug regimens must be closely followed in order to be successful. Having a support person
      watch a patient take his or her anti-HIV drugs each day may help a patient follow his or her
      regimen. This study will see if patient-chosen treatment supporters help patients take HIV
      medicines correctly and improve their health.

      Study hypothesis: The mean change in CD4 count at 12 and 24 months will be significantly
      higher in the directly observed therapy-highly active antiretroviral therapy (DOT-HAART) arm
      as compared to the self-administered arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      South Africa has one of the worst and fastest growing HIV epidemics in the world. Highly
      active antiretroviral therapy (HAART) has been shown both at the individual and public health
      levels to reduce morbidity, mortality, and vertical and possibly horizontal HIV transmission.
      However, expenses, feasibility, long-term adherence, and effective delivery of HAART remain
      formidable barriers, particularly in developing nations. Recently, international initiatives
      have provided hope for widespread use of HAART at affordable cost in sub-Saharan Africa.
      Simplified, once-daily HAART regimens with directly observed therapy (DOT) may help to
      achieve high levels of treatment adherence, a key component for long-term viral suppression
      and treatment success. Peer advocates have been used to improve adherence with medical
      therapies in a variety of settings. This study will evaluate the effectiveness and
      feasibility of DOT using patient-nominated peer supervisors to improve adherence to HAART in
      HIV infected adults in South Africa.

      Participants will be randomly assigned to either Peer-DOT-HAART or self-administration of a
      once-daily combination of the Western Cape Province ART program medications for 24 months.
      Study measures will include CD4 cell count and HIV viral load, adherence questionnaires,
      genotypic HAART resistance testing, and incidence of new or recurrent opportunistic
      infections.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    DSMB stopped trial for futility
  </why_stopped>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of DOT Compared to Self-administered Treatment as Measured by HIV Viral Load at 12 Months of Treatment</measure>
    <time_frame>at 12 and 24 months of treatment</time_frame>
    <description>Proportion of Patients with HIV RNA Levels of &lt;400 at 12 Months - Intention-to-treat</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of DOT Compared to Self-administered Treatment as Measured by HIV Viral Load at 24 Months of Treatment</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of Patients with HIV RNA Levels of &lt;400 Copies/mL at 24 Months [Intention-to-treat (ITT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunological Response: Median CD4 (IQR) Cell Count Increase From Baseline at 12 Months by Study Arm</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunological Response: Median CD4 (IQR) Cell Count Increase From Baseline at 24 Months by Study Arm</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">274</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of a patient nominated peer supporter who will observe the morning dose of ARVs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Self administration of ARVs</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Directly Observed Therapy</intervention_name>
    <description>Use of a patient nominated peer supporter who will observe the morning dose of ARVs</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected

          -  Viral load greater than 1000 copies/ml

          -  CD4 count of 200 cells/mm3 or less, or World Health Organization Stage 4 disease

          -  Living in the area of the study site

          -  Had a known address for more than 3 months

          -  Willing to nominate a treatment supervisor (a close family member, sexual partner,
             friend, or community volunteer) to observe daily ingestion of tablets

          -  Willing to disclose HIV status to a treatment supervisor and ready to commit to
             long-term antiretroviral therapy

          -  Acceptable methods of contraception

        Exclusion Criteria:

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E Chaisson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <results_reference>
    <citation>Nachega JB, Chaisson RE, Goliath R, Efron A, Chaudhary MA, Ram M, Morroni C, Schoeman H, Knowlton AR, Maartens G. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS. 2010 Jun 1;24(9):1273-80. doi: 10.1097/QAD.0b013e328339e20e.</citation>
    <PMID>20453627</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2004</study_first_submitted>
  <study_first_submitted_qc>February 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2004</study_first_posted>
  <results_first_submitted>June 1, 2010</results_first_submitted>
  <results_first_submitted_qc>June 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2010</results_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Dr. Richard Chaisson</investigator_full_name>
    <investigator_title>Director, Center for TB Research</investigator_title>
  </responsible_party>
  <keyword>Directly Observed Therapy</keyword>
  <keyword>DOT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study site was a public sector ART clinic at the GF Jooste Hospital, a secondary level facility in Cape Town, Western Cape province of South Africa, serving several peri-urban townships. Enrollment began February 13, 2005, and ended on July 7, 2007, with the last follow-up occurring on July 25, 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Peer Supporter</title>
          <description>Use of a patient nominated peer supporter who sill observe the morning dose of ARVs</description>
        </group>
        <group group_id="P2">
          <title>Self Administration</title>
          <description>Self administration of ARVs</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77">111 completed week 48, 77 completed week 96.</participants>
                <participants group_id="P2" count="68">102 completed week 48, 68 completed week 96</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early study Closure</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peer Supporter</title>
          <description>Use of a patient nominated peer supporter who sill observe the morning dose of ARVs</description>
        </group>
        <group group_id="B2">
          <title>Self Administration</title>
          <description>Self administration of ARVs</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="137"/>
            <count group_id="B2" value="137"/>
            <count group_id="B3" value="274"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="9.7"/>
                    <measurement group_id="B2" value="36.7" spread="9.2"/>
                    <measurement group_id="B3" value="36.2" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Impact of DOT Compared to Self-administered Treatment as Measured by HIV Viral Load at 12 Months of Treatment</title>
        <description>Proportion of Patients with HIV RNA Levels of &lt;400 at 12 Months - Intention-to-treat</description>
        <time_frame>at 12 and 24 months of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peer Supporter</title>
            <description>Use of a patient nominated peer supporter who sill observe the morning dose of ARVs</description>
          </group>
          <group group_id="O2">
            <title>Self Administration</title>
            <description>Self administration of ARVs</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of DOT Compared to Self-administered Treatment as Measured by HIV Viral Load at 12 Months of Treatment</title>
          <description>Proportion of Patients with HIV RNA Levels of &lt;400 at 12 Months - Intention-to-treat</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unadjusted endpoint analyses were conducted on an intention-to-treat basis using all patients enrolled to compare outcomes in the DOT vs. Self-ART arm. For viral load analyses, missing values were considered detectable (missing¼failure analysis). As-treated analyses were also conducted using patients remaining in the study with available data.Crosssectional comparisons between study groups were conducted using two sample t-test,Wilcoxon rank-sum test,chi-squared orFisher’s exact and Kaplan–Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <p_value_desc>Logistic regression analysis &amp; Cox proportional hazards regression analyses were performed to compare outcomes after adjusting for the relevant covariates,including study arm, age, sex, baseline CD4 cell counts and viral load and pill count adherence</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>one degree of freedom</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Impact of DOT Compared to Self-administered Treatment as Measured by HIV Viral Load at 24 Months of Treatment</title>
        <description>Proportion of Patients with HIV RNA Levels of &lt;400 Copies/mL at 24 Months [Intention-to-treat (ITT)</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peer Supporter</title>
            <description>Use of a patient nominated peer supporter who sill observe the morning dose of ARVs</description>
          </group>
          <group group_id="O2">
            <title>Self Administration</title>
            <description>Self administration of ARVs</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of DOT Compared to Self-administered Treatment as Measured by HIV Viral Load at 24 Months of Treatment</title>
          <description>Proportion of Patients with HIV RNA Levels of &lt;400 Copies/mL at 24 Months [Intention-to-treat (ITT)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unadjusted endpoint analyses were conducted on an intention-to-treat basis using all patients enrolled to compare outcomes in the DOT vs. Self-ART arm. For viral load analyses, missing values were considered detectable (missing¼failure analysis). As-treated analyses were also conducted using patients remaining in the study with available data.Crosssectional comparisons between study groups were conducted using two sample t-test,Wilcoxon rank-sum test,chi-squared orFisher's exact and Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <p_value_desc>Logistic regression analysis &amp; Cox proportional hazards regression analyses were performed to compare outcomes after adjusting for the relevant covariates,including study arm, age, sex, baseline CD4 cell counts and viral load and pill count adherence</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>one degree of freedom</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunological Response: Median CD4 (IQR) Cell Count Increase From Baseline at 12 Months by Study Arm</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peer Supporter</title>
            <description>Use of a patient nominated peer supporter who sill observe the morning dose of ARVs</description>
          </group>
          <group group_id="O2">
            <title>Self Administration</title>
            <description>Self administration of ARVs</description>
          </group>
        </group_list>
        <measure>
          <title>Immunological Response: Median CD4 (IQR) Cell Count Increase From Baseline at 12 Months by Study Arm</title>
          <units>cells/uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185" lower_limit="108" upper_limit="276"/>
                    <measurement group_id="O2" value="160" lower_limit="78" upper_limit="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unadjusted endpoint analyses were conducted on an intention-to-treat basis using all patients enrolled to compare outcomes in the DOT vs. Self-ART arm. For viral load analyses, missing values were considered detectable (missing¼failure analysis). As-treated analyses were also conducted using patients remaining in the study with available data.Crosssectional comparisons between study groups were conducted using two sample t-test,Wilcoxon rank-sum test,chi-squared orFisher's exact and Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <p_value_desc>Logistic regression analysis &amp; Cox proportional hazards regression analyses were performed to compare outcomes after adjusting for the relevant covariates,including study arm, age, sex, baseline CD4 cell counts and viral load and pill count adherence</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunological Response: Median CD4 (IQR) Cell Count Increase From Baseline at 24 Months by Study Arm</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peer Supporter</title>
            <description>Use of a patient nominated peer supporter who sill observe the morning dose of ARVs</description>
          </group>
          <group group_id="O2">
            <title>Self Administration</title>
            <description>Self administration of ARVs</description>
          </group>
        </group_list>
        <measure>
          <title>Immunological Response: Median CD4 (IQR) Cell Count Increase From Baseline at 24 Months by Study Arm</title>
          <units>cells/uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281" lower_limit="144" upper_limit="403"/>
                    <measurement group_id="O2" value="262" lower_limit="149" upper_limit="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unadjusted endpoint analyses were conducted on an intention-to-treat basis using all patients enrolled to compare outcomes in the DOT vs. Self-ART arm. For viral load analyses, missing values were considered detectable (missing¼failure analysis). As-treated analyses were also conducted using patients remaining in the study with available data.Crosssectional comparisons between study groups were conducted using two sample t-test,Wilcoxon rank-sum test,chi-squared orFisher's exact and Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <p_value_desc>Logistic regression analysis &amp; Cox proportional hazards regression analyses were performed to compare outcomes after adjusting for the relevant covariates,including study arm, age, sex, baseline CD4 cell counts and viral load and pill count adherence</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event data was collected throughout the duration of the study. It was assessed at each clinic visit and if the subject presented between visits.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Peer Supporter</title>
          <description>Use of a patient nominated peer supporter who sill observe the morning dose of ARVs</description>
        </group>
        <group group_id="E2">
          <title>Self Administration</title>
          <description>Self administration of ARVs</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>DAIDS Grade IV AE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>AIDS-Defining Illness</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="137"/>
                <counts group_id="E2" events="35" subjects_affected="31" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>DAIDS Grade III Event</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="137"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>New Diagnosis/Worsening Medical Condition</sub_title>
                <counts group_id="E1" events="39" subjects_affected="32" subjects_at_risk="137"/>
                <counts group_id="E2" events="52" subjects_affected="37" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Intervention was stopped at 12 months, transition phase did not ensure that participants developed a set of adherence strategies to replace DOT-ART. Low incidence of AIDS-defining illness and death limit our ability to make final conclusions</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Richard E. Chaisson</name_or_title>
      <organization>Johns Hopkins University Center for TB Research</organization>
      <phone>4109551755</phone>
      <email>rchaiss@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

